Review Article
Tuberculous Meningitis, What’s New?
Sanaz Lolachi1, Janssens JP2 and Dan Adler2*
1Department of Internal Medicine, Hospital la Tour, Geneva, Switzerland
2Division of Pulmonary Diseases, Geneva University Hospitals and University of Geneva, Switzerland
- *Corresponding Author:
- Dan Adler
Division of Pneumology, University of Geneva Hospitals
4 Rue Gabrielle-Perret-Gentil, 1211 University of Geneva 14, Switzerland
Tel: +41 22 372 95 46
E-mail: Dan.Adler@hcuge.ch
Received Date: April 21, 2017; Accepted Date: May 19, 2017; Published Date: May 22, 2017
Citation: Lolachi S, Janssens JP, Adler D (2017) Tuberculous Meningitis, What’s New?. J Neuroinfect Dis 8:248. doi: 10.4172/2314-7326.1000248
Copyright: © 2017 Lolachi S, et al. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Tuberculous meningitis may not be the most common cause of bacterial meningitis in non-endemic countries, but it is certainly the most dangerous form of meningitis with a high morbidity and mortality. The diagnosis is difficult and a delay in treatment initiation can lead to poor outcomes, including severe neurological disability. In the setting of world globalization and frequent travel to endemic areas, it is important that physicians be acquainted with this disease. This review discusses the most recent advances related to diagnosis and treatment regimens, including the challenges associated with the treatment of individuals with concomitant human immunodeficiency virus infection as well as advances in vaccination against mycobacterium tuberculosis.
